Literature DB >> 1534176

Does ondansetron attenuate amphetamine-induced behaviour in human volunteers?

P H Silverstone1, B Johnson, P J Cowen.   

Abstract

The effect of the 5-HT3 receptor antagonist, ondansetron, on the decrease in hunger produced by amphetamine was assessed in nine male volunteers using a double-blind cross-over design. Amphetamine (15 mg orally) produced a significant decrease in self-ratings of hunger 2.5 h after administration. This effect was significantly attenuated by pre-treatment with ondansetron (12 mg orally over 24 h). These findings in humans are consistent with data from animal studies suggesting that ondansetron can attenuate certain catecholamins-mediated behaviours produced by amphetamine. However, explanations founded on pharmacokinetic factors cannot be presently excluded.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534176     DOI: 10.1007/bf02244979

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  9 in total

Review 1.  The psychopharmacology of 5-HT3 receptors.

Authors:  B Costall; R J Naylor; M B Tyers
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

2.  The influence of levodopa on gastric emptying in man.

Authors:  D R Robertson; A G Renwick; N D Wood; N Cross; B S Macklin; J S Fleming; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

3.  Role of brain monoamines in the anorectic activity of mazindol and d-amphetamine in the rat.

Authors:  R Samanin; C Bendotti; S Bernasconi; E Borroni; S Garattini
Journal:  Eur J Pharmacol       Date:  1977-05-15       Impact factor: 4.432

4.  Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain.

Authors:  B Costall; A M Domeney; R J Naylor; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

5.  The effect of the dopamine receptor blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man.

Authors:  T Silverstone; J Fincham; B Wells; M Kyriakides
Journal:  Neuropharmacology       Date:  1980-12       Impact factor: 5.250

6.  Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat.

Authors:  J M Barnes; N M Barnes; S Champaneria; B Costall; R J Naylor
Journal:  Neuropharmacology       Date:  1990-11       Impact factor: 5.250

7.  GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

Authors:  N J Talley; S F Phillips; A Haddad; L J Miller; C Twomey; A R Zinsmeister; R L MacCarty; A Ciociola
Journal:  Dig Dis Sci       Date:  1990-04       Impact factor: 3.199

Review 8.  Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications.

Authors:  B G Hoebel; L Hernandez; D H Schwartz; G P Mark; G A Hunter
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

9.  Differential inhibitory effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release.

Authors:  E Carboni; E Acquas; R Frau; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1989-05-30       Impact factor: 4.432

  9 in total
  3 in total

1.  Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron.

Authors:  E C Warburton; M H Joseph; J Feldon; I Weiner; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

Review 2.  Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse.

Authors:  R M Hagan; G J Kilpatrick; M B Tyers
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 3.  The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.

Authors:  E A Engleman; Z A Rodd; R L Bell; J M Murphy
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.